management of crs and icans after car-t therapy for all
Published 3 years ago • 539 plays • Length 1:23Download video MP4
Download video MP3
Similar videos
-
5:54
investigating the co-occurrence of crs and icans after car-t therapy & the need for novel therapies
-
1:31
strategies to minimize the occurrence of crs and icans in patients treated with car-t therapy
-
2:09
treating crs and icans: current approaches and future outlooks
-
3:43
car t-cell toxicity: crs, icans and prolonged cytopenias
-
6:07
managing crs in car t-cell therapy
-
2:06
managing and treating crs, neurological toxicity and cytopenias associated with car-t therapy
-
3:47
update on the guidelines for the diagnosis, grading & management of icaht following car-t therapy
-
3:19
car-t and neurotoxicity: frequency and management
-
1:43
management of car-t related side effects
-
1:16
car-t treatment journey and the role of the nurse
-
1:59
nursing perspectives: a look at icans in car-t
-
4:24
investigating production failure and out-of-specification production of car t-cell therapeutics
-
2:31
remote management of patients undergoing car t-cell therapy
-
1:49
car-t cell approaches in cll: current progress & future directions
-
1:28
assessment of car-t and tcr adverse events
-
2:05
the cost-effectiveness of car t-cell therapy
-
2:51
novel agents vs. standard chemotherapy for first-line salvage treatment following car-t in lbcl
-
4:10
car t-cell therapy for all
-
1:35
key mechanisms of resistance to car t-cell therapy